Through a GMP-compliant nuclear pharmacy facility, Careview produces a wide range of radiopharmaceutical tracers used for both clinical and research PET imaging. These specialized tracers help physicians visualize biological processes in the body, supporting accurate diagnosis, disease evaluation, and treatment planning. RadiotracerPrimary Use18F-FDGImaging glucose metabolism and detecting many types of cancer68Ga-PSMADetection and evaluation of prostate cancer68Ga-DOTA-TATE / DOTA-NOC / DOTA-TOCIdentification of neuroendocrine tumors11C-AcetateAssessment of liver cancer18F-Flutemetamol (Vizamyl)Imaging related to Alzheimer’s disease18F-PSMAEvaluation of prostate cancer18F-CholineDetection of primary prostate cancer18F-Sodium FluorideImaging for bone metastases18F-Fluorothymidine (FLT)Assessment of tumor cell proliferation18F-PE2IImaging related to brain disorders18F-MISOIdentification of tumor hypoxia11C-RacloprideEvaluation of Parkinson’s disease11C-MethionineImaging for brain tumors11C-PBR28Assessment of brain inflammation

KHealth Corporation also supports theranostic nuclear medicine through the supply of Lutetium‑177 PSMA, a targeted radioligand therapy used for the treatment of advanced prostate cancer. These radiopharmaceuticals enable physicians to diagnose, monitor, and treat diseases using highly specialized molecular imaging techniques. Through advanced molecular imaging using Positron Emission Tomography–Computed Tomography (PET‑CT), clinicians can visualize biological processes occurring within the body at the cellular level. Radiopharmaceuticals emit signals that allow physicians to detect disease early, assess treatment response, monitor progression, and identify recurrence with high sensitivity and specificity.

Careview supports advanced nuclear medicine by providing specialized radiopharmaceutical tracers used in PET/CT imaging and targeted therapy. Our facility produces key tracers such as FDG, F-PSMA, Lu-PSMA, and FBB, which play important roles in the detection, evaluation, and treatment of various diseases. These radiotracers enable physicians to assess metabolic activity, identify prostate cancer, perform targeted radionuclide therapy, and support neurological imaging related to cognitive conditions. By maintaining strict quality and safety standards, Careview ensures reliable radiopharmaceutical supply to support accurate diagnostics and effective patient care.

Careview offers facility and equipment leasing options designed to support training programs, professional workshops, and specialized technical activities. Our services may also include consultancy support in areas such as medical physics, radiation safety, and GMP-related processes, helping organizations maintain high operational and regulatory standards.

Careview collaborates with leading research institutions and healthcare organizations to support advancements in nuclear medicine and diagnostic imaging. Through these partnerships, we contribute to initiatives focused on improving imaging technologies and developing innovative radiotracers for better disease detection. Our team also works closely with nuclear medicine specialists across both public and private healthcare sectors to support research programs and grant initiatives aimed at enhancing early detection and diagnosis of cancer and other medical conditions.